Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Finance Watch: 5AM, Longevity Close Funds, New Incubators Launch To Support Early-Stage Companies

Executive Summary

News of 5AM's two latest venture funds follows the launch of Longevity Vision Fund as well as LA BioMed's and RUNLABS’ announcements that they will open new incubators in 2019. Also, Passage Bio launches with $115.5m, but the largest recent VC deal was HaiHe's $146.6m financing.

Advertisement

Related Content

New Option For Uncontrolled Epilepsy On Horizon As US Accepts Cenobamate NDA
Finance Watch: Three New Funds, Including Former Amgen R&D Head Harper's Next Venture
Finance Watch: Investments In Regenerative Therapies Surged In The Second Quarter
CARB-X Partnership Puts Antibiotics' Future In Biotech Startups' Hands
VC Roundup: Three New Funds Close As Small, Early Financings Bounce Back
3-V Biosciences raises $28.5m in Series D
UPDATED: Clovis buys EOS for $200m after 2-year interest in lucitanib
China’s SIMM, French Drugmaker Servier To Collaborate On Anti-Tumor Medicine R&D

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC124678

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel